Compare Stocks → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AFIBNASDAQ:DCTHNASDAQ:GCTKNASDAQ:NVCN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFIBAcutus Medical$0.17$0.19$0.16▼$1.09$4.96M0.191.89 million shs47,123 shsDCTHDelcath Systems$5.45-2.7%$4.52$2.25▼$7.99$138.65M0.53225,364 shs190,738 shsGCTKGlucoTrack$0.48-36.9%$0.38$0.13▼$1.00$12.82M0.29182,400 shs1.58 million shsNVCNNeovasc$30.03$29.69$4.59▼$30.07$82.28M1.756,993 shs1 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFIBAcutus Medical+0.42%+1.63%-9.03%-24.19%-79.48%DCTHDelcath Systems+1.63%+18.39%+19.66%+30.23%-5.08%GCTKGlucoTrack-15.65%+44.84%+130.99%+242.19%+16.94%NVCNNeovasc0.00%0.00%0.00%0.00%0.00%A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAFIBAcutus MedicalN/AN/AN/AN/AN/AN/AN/AN/ADCTHDelcath Systems3.0349 of 5 stars3.52.00.00.03.14.20.6GCTKGlucoTrack0.173 of 5 stars0.03.00.00.01.12.50.0NVCNNeovascN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAFIBAcutus MedicalN/AN/AN/AN/ADCTHDelcath Systems3.00Buy$18.50239.45% UpsideGCTKGlucoTrackN/AN/AN/AN/ANVCNNeovascN/AN/AN/AN/ACurrent Analyst RatingsLatest NVCN, DCTH, GCTK, and AFIB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAFIBAcutus Medical$7.16M0.69N/AN/A($0.03) per share-5.56DCTHDelcath Systems$2.07M66.98N/AN/A$0.72 per share7.57GCTKGlucoTrackN/AN/AN/AN/A$0.15 per shareN/ANVCNNeovasc$3.81M21.60N/AN/A$5.77 per share5.20Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAFIBAcutus Medical-$81.66M-$1.24N/A∞N/A-166.79%-35.31%-13.43%5/9/2024 (Estimated)DCTHDelcath Systems-$47.68M-$2.97N/AN/AN/A-2,308.86%-563.60%-111.13%5/27/2024 (Estimated)GCTKGlucoTrack-$7.10M-$0.37N/A∞N/AN/A-172.38%-127.42%5/10/2024 (Estimated)NVCNNeovasc-$41.20M-$15.08N/A∞N/A-1,082.92%-127.25%-80.31%N/ALatest NVCN, DCTH, GCTK, and AFIB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023GCTKGlucoTrackN/A-$0.10-$0.10-$0.10N/AN/A3/26/2024Q4 23DCTHDelcath Systems-$0.67-$0.48+$0.19-$0.48$0.48 million$0.54 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAFIBAcutus MedicalN/AN/AN/AN/AN/ADCTHDelcath SystemsN/AN/AN/AN/AN/AGCTKGlucoTrackN/AN/AN/AN/AN/ANVCNNeovascN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAFIBAcutus Medical1.102.442.22DCTHDelcath SystemsN/A2.262.06GCTKGlucoTrack0.063.223.22NVCNNeovasc0.802.962.85OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAFIBAcutus Medical56.91%DCTHDelcath Systems61.12%GCTKGlucoTrack10.92%NVCNNeovasc1.64%Insider OwnershipCompanyInsider OwnershipAFIBAcutus Medical3.50%DCTHDelcath Systems17.94%GCTKGlucoTrack17.70%NVCNNeovascN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAFIBAcutus Medical23029.72 million28.68 millionOptionableDCTHDelcath Systems7625.44 million20.88 millionOptionableGCTKGlucoTrack626.76 million22.02 millionNot OptionableNVCNNeovasc492.74 millionN/ANot OptionableNVCN, DCTH, GCTK, and AFIB HeadlinesSourceHeadlineTop Small-Cap Stocks for May 2023 - Investopedianews.google.com - May 13 at 9:38 AMFDA accepts application for Roche's Vabysmo for the - GlobeNewswirenews.google.com - May 9 at 2:18 AMNew treatment option opens avenues in geographic atrophy - Healionews.google.com - May 8 at 9:18 PMPachychoroid neovasculopathy has clinical properties that differ ... - Nature.comnews.google.com - May 8 at 9:18 PMThe NOD audit provides data and insights for the management for ... - Modern Retinanews.google.com - May 8 at 9:18 PMShockwave Medical Reports First Quarter 2023 Financial Results - GlobeNewswirenews.google.com - May 8 at 4:17 PMHeart valve repair and replacement devices market size to grow by ... - Benzinganews.google.com - May 5 at 9:03 PMASCRS: Prediction of imminent conversion to neovascular AMD ... - Optometry Timesnews.google.com - May 5 at 4:02 PMFaricimab in Treatment-Resistant nARMD | OPTH - Dove Medical Pressnews.google.com - May 5 at 12:24 AMRestoring vision through retinal ganglion cell repopulation - Ophthalmology Times Europenews.google.com - May 5 at 12:24 AMSTAR Trial: Surgery Not Superior to Pneumatic Displacement for ... - MD Magazinenews.google.com - May 4 at 7:24 PMThe NOD audit: Insights into the current state of management for ... - Nature.comnews.google.com - May 4 at 8:40 AMOn the horizon: Treatments for both forms of AMD - Ophthalmology Times Europenews.google.com - May 3 at 10:56 AMBiosimilar Ranibizumab Displays Comparable Safety, Efficacy to ... - The Center for Biosimilarsnews.google.com - April 28 at 3:22 PMReal World Evidence Supporting GA Therapy Management Strategies - AJMC.com Managed Markets Networknews.google.com - April 28 at 10:22 AMLow-vision services improve vision, quality of life in patients with ... - Healionews.google.com - April 28 at 10:22 AMNew Vabysmo data suggest greater retinal drying versus aflibercept ... - GlobeNewswirenews.google.com - April 25 at 6:55 PMNew treatment tackles both forms of AMD - Ophthalmology Timesnews.google.com - April 25 at 6:55 PMPrice Variation in Economic Evaluations of Infliximab Could ... - The Center for Biosimilarsnews.google.com - April 25 at 1:32 AM1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Yahoo Financenews.google.com - April 25 at 1:32 AMAccel Research expands reach with acquisition of two Florida trial ... - FierceBiotechnews.google.com - April 24 at 3:16 PMReport: Boston Scientific considering massive deal to acquire ... - Cardiovascular Businessnews.google.com - April 24 at 3:16 PMBoston Sci Rumored to Be Interested in Acquiring Shockwave - Medical Device and Diagnostics Industrynews.google.com - April 21 at 4:24 PMThe Future of the Structural Heart Disease Intervention Devices ... - Digital Journalnews.google.com - April 21 at 10:58 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcutus MedicalNASDAQ:AFIBAcutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. The company was incorporated in 2011 and is headquartered in Carlsbad, California.Delcath SystemsNASDAQ:DCTHDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.GlucoTrackNASDAQ:GCTKGlucoTrack, Inc., a medical device company, focuses on designing, developing, and commercializing non-invasive glucose monitoring devices for use by people with diabetes in the United States. It develops GlucoTrack, a non-invasive blood glucose monitor that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.NeovascNASDAQ:NVCNNeovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.